Q&A: A.J. Kazimi, Cumberland Pharmaceuticals CEO of biopharmaceutical company talks what’s next after $100 million deal with Canadian-based firm • CYN THIA YELDELL A NDERSO N • MAY 4, 2026 Cumberland Pharmaceuticals Inc. recently announced a $100…
Q&A: A.J. Kazimi, Cumberland Pharmaceuticals
CEO of biopharmaceutical company talks what’s next after
$100 million deal with Canadian-based firm
• CYN THIA YELDELL A NDERSO N
• MAY 4, 2026
Cumberland Pharmaceuticals Inc. recently announced a $100 million deal with
Canadian-based global health company Apotex, indicating a major shift in
strategy for the Nashville-based publicly traded company.
In an interview with the Post, Cumberland CEO A.J. Kazimi explains why he sees
the company as, in effect, “splitting in two,” and how business is pivoting from a
hybrid concept to an entity laser-focused on its drug development pipeline.
You have described the recent transaction as a strategic
transformation for the company. Before we get into the details of the
deal, can you provide context on what led to it?
A.J. Kazimi
Photo: Cumberland Pharmaceuticals
cum
We really enjoyed an outstanding year in 2025 and made
progress on all key fronts. Our revenues last year grew over
30 percent in the fourth quarter and nearly 20 percent for the
full year. So that's very significant revenue growth, and that
resulted in favorable cash flow from operations. That's from
the financial perspective.
From the operating perspective, we added a new brand, a medicine that's used to
treat the leading cause of stomach infections. Part of our strategy has been to add
select brands to the portfolio. And later last year, we were able to close on a
transaction to add that brand. The other big development was the announcement of
a breakthrough clinical study report, clinical study results from our program
developing a new treatment for boys with Duchenne muscular dystrophy. We've
been working to protect their hearts, and we concluded a phase two study that
demonstrated our product could be safely delivered and show improvement in their
heart function.
In addition to all of that, as we distributed our medicines here in the United States,
we were able to add some new markets with approvals overseas for a couple of our
products. All of that meant we ended the year and moved into the new year in a very
strong position and with terrific momentum.
Did that growth put the company on the radar of
potential investors?
Other companies have been watching us and our market value really didn't reflect
the progress we had made. If you look at our share price and how many shares we
have outstanding, our market value was hovering around $40 to $45 million, which is
rather small, and that's in spite of all that progress I just mentioned, and so we saw
an opportunity here to literally unlock value through this strategic transaction. And
what we're doing is we are in effect, splitting our company into two. The commercial
brands and team will be integrated into the U.S.-branded business of the largest
Canadian pharma company. They are a very strong player in generic products. Their
strategy is now to expand their branded business, and they see the Cumberland
portfolio as a catalyst in helping them do so. Our brands and our commercial team
will move and be combined into the Apotex U.S.-branded operation.
You said the company is, in effect splitting in two, what
is the other half?
The other half is our development pipeline. And there we are working on new
medicines for the future. Our goal is to deliver treatments for problems, medical
conditions today that have no cure. We can really benefit patients that way, and we
feel we can create a lot of new value. So that's the essence of what we're doing and
why we're doing it. I said that $40 to $45 million was the market capitalization for our
company, and this transaction will provide us with $100 million of cash
consideration. Just through this transaction, we're more than doubling the value of
the company, and we still retain our pipeline, which we actually think is the more
valuable part of our business.
Why is the pipeline the business area chosen to lead the
company in this new direction?
It provides us with the opportunity to really focus on bringing these new medicines to
the market, and frankly, doing a lot of good with them. If we're dealing in diseases
that today have no treatment, it's very rewarding to be able to bring solutions for
these patients that need them. Also, the markets that we're working in through our
pipeline are much larger than the ones that we were selling products in today. So
that is very exciting to not only be able to help new patients that don't have anything
successful that effectively treats their condition, and to also create a lot of value for
our shareholders at the same time.
When we look at our industry, the smaller companies in this field, typically, they're
either a commercial business or a development business. We've been a bit of a
hybrid. I think that becoming a pure development company will help the investment
community better understand our business.
You have a second company, Cumberland Emerging
Technologies Inc., how will the transaction impact that
business?
Yeah, a couple things. First of all, we have a second company called Cumberland
Emerging Technologies that we abbreviate CET, and CET runs the Nashville Life
Science incubator, the Nashville Life Science Center, where we host biomedical
startups and give an initial home as they start to build their business. We'll continue
to operate that local Life Science Center to support the growth of this industry in this
part of the country.
Over the years, we've worked closely with the Vanderbilt University Medical Center
and we have a strong partnership there, and we'll look forward to continuing to work
with them to advance new medicines, to build upon their discoveries and collaborate
to improve patient care. Those are two important areas that will remain with this
change that's going to occur.
What’s next for Cumberland Pharmaceuticals?
The first order of business is to complete and close the transaction that we just
announced, The next step is to go to our shareholders for approval. We estimate
that will take a couple months. We'll then be transitioning the commercial operations
to Apotex, and that will take some effort over a period of time. But there will be more
milestones ahead, and it's really around the studies and the data that we are
creating in our three different development programs.
When we think about a major strategy shift, a major transaction for a company like
this, I like to consider all of the constituencies that are impacted. First of all, we've
got to do what's right for our shareholders, and especially as a publicly-traded
company, we've got to look after the interest of our shareholders, but we also want
to take care of our employees, that's an important group to look after. In addition to
that, we think about our partners and those relationships and how to preserve and
build upon those, and we think about patients, perhaps most importantly, and how a
transaction like this is going to impact patients. When you put two branded
businesses together, you can create more critical mass. You can create stronger
distribution; you can get these medicines out to more patients. So that's important to
us. And then finally, the community. What's the impact on the community?
Cumberland's not going anywhere. Cumberland is going to be here, and we're going
to continue in our leadership role for the life sciences industry in this part of the
country, and continue to grow and build upon what we have here and contribute
back to the community.